ScholarIQanswers from OpenAlex & ORCID
Juliann Chmielecki
ResearcherPublications, citations & collaboration network
Juliann Chmielecki is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Juliann Chmielecki have?
ScholarIQindexed works
Juliann Chmielecki has 376 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Juliann Chmielecki have?
ScholarIQcitation count
Juliann Chmielecki has 23,985 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Juliann Chmielecki?
ScholarIQh-index
Juliann Chmielecki has an h-index of 57 in OpenAlex.
What is the i10-index of Juliann Chmielecki?
ScholarIQi10-index
Juliann Chmielecki has an i10-index of 91 in OpenAlex.
What is the ORCID of Juliann Chmielecki?
ScholarIQorcid
The ORCID for Juliann Chmielecki is on the source record.
What is the OpenAlex record for Juliann Chmielecki?
ScholarIQopenalex
The OpenAlex for Juliann Chmielecki is on the source record.
What are the most-cited papers on Juliann Chmielecki?
ScholarIQmost cited works
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
Zachary R. Chalmers, Caitlin Connelly, David Fabrizio, Laurie M. Gay, Siraj M. Ali, Riley Ennis, Alexa B. Schrock, Brittany Campbell, Adam Shlien, Juliann Chmielecki, Franklin W. Huang, Yuting He, James Sun, Uri Tabori, Mark Kennedy, Daniel S. Lieber, Steven Roels, Jared White, Geoffrey A. Otto, Jeffrey S. Ross, Levi A. Garraway, Vincent A. Miller, P. J. Stephens, Garrett M. Frampton
Activation of MET via Diverse Exon 14 Splicing Alterations Occurs in Multiple Tumor Types and Confers Clinical Sensitivity to MET Inhibitors
Garrett M. Frampton, Siraj M. Ali, Mark R. Rosenzweig, Juliann Chmielecki, Xinyuan Lu, Todd M. Bauer, Mikhail Akimov, José A. Bufill, Carrie B. Lee, David Jentz, Rick Hoover, Sai‐Hong Ignatius Ou, Ravi Salgia, Timothy J. Brennan, Zachary R. Chalmers, Savina Jaeger, Alan Huang, Julia A. Elvin, Rachel Erlich, Alex Fichtenholtz, Kyle Gowen, Joel Greenbowe, Adrienne Johnson, Depinder Khaira, Caitlin McMahon, Eric M. Sanford, Steven Roels, Jared White, Joel Greshock, Robert Schlegel, Doron Lipson, Roman Yelensky, Deborah Morosini, Jeffrey S. Ross, Eric A. Collisson, Malte Peters, Philip J. Stephens, Vincent A. Miller
Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Lung Cancer: Distinct Natural History of Patients with Tumors Harboring the T790M Mutation
Geoffrey R. Oxnard, Maria E. Arcila, Camelia S. Sima, Gregory J. Riely, Juliann Chmielecki, Mark G. Kris, William Pao, Marc Ladanyi, Vincent A. Miller
Osimertinib in Patients With Epidermal Growth Factor Receptor Mutation–Positive Non–Small-Cell Lung Cancer and Leptomeningeal Metastases: The BLOOM Study
James Chih‐Hsin Yang, Sang-We Kim, Dong‐Wan Kim, Jong Seok Lee, Byoung Chul Cho, Jin-Seok Ahn, Dae H. Lee, Tae Min Kim, Jonathan W. Goldman, Ronald B. Natale, Andy Brown, Barbara Collins, Juliann Chmielecki, Karthick Vishwanathan, Ariadna Mendoza‐Naranjo, Myung‐Ju Ahn
Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study
Suresh S. Ramalingam, Yi Cheng, C. Zhou, Y. Ohe, Fumio Imamura, Byoung Chul Cho, Meng‐Chih Lin, Margarita Majem, Riyaz Shah, Yuri Rukazenkov, A. Todd, Aleksandra Markovets, J. Carl Barrett, Juliann Chmielecki, Jhanelle E. Gray